BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN) $92.67 -2.27 (-2.39%) (As of 11:39 AM ET) Add Compare Share Share Today's Range$92.62▼$94.3350-Day Range$76.22▼$94.9452-Week Range$76.02▼$117.77Volume422,118 shsAverage Volume1.41 million shsMarket Capitalization$17.46 billionP/E Ratio120.35Dividend YieldN/APrice Target$112.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability BioMarin Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.61 Rating ScoreUpside/Downside18.7% Upside$112.65 Price TargetShort InterestHealthy1.64% of Shares Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment1.12Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth84.75%From $1.18 to $2.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.83 out of 5 starsMedical Sector42nd out of 960 stocksPharmaceutical Preparations Industry9th out of 381 stocks 3.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.61, and is based on 14 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $112.65, BioMarin Pharmaceutical has a forecasted upside of 18.7% from its current price of $94.94.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.64% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 6.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 3.4 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for BioMarin Pharmaceutical this week, compared to 5 articles on an average week.Search InterestOnly 12 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows7 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.84% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions92.78% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 84.75% in the coming year, from $1.18 to $2.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 123.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 120.64.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 123.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.40.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 1.44. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More BMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRN Stock News HeadlinesDecember 1, 2023 | markets.businessinsider.comStrategic Advancements and Long-Term Gains: Buy Rating on BioMarin Amidst Roctavian’s European RolloutDecember 1, 2023 | finance.yahoo.comWhy Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report?December 8, 2023 | Edge On The Street (Ad)Energy Storage Trend Ignites Frenzy Over Vanadium SupplyAs the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.November 30, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Ascendis Pharma (ASND) and BioMarin Pharmaceutical (BMRN)November 28, 2023 | finance.yahoo.comBioMarin prices hemophilia gene therapy at nearly 29,000 euros per vial in GermanyNovember 28, 2023 | finance.yahoo.comBioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in GermanyNovember 23, 2023 | finance.yahoo.comBioMarin Pharmaceutical's (NASDAQ:BMRN) investors will be pleased with their 13% return over the last three yearsNovember 15, 2023 | msn.comWells Fargo starts BioMarin at overweight, cites activist involvementDecember 8, 2023 | Edge On The Street (Ad)Energy Storage Trend Ignites Frenzy Over Vanadium SupplyAs the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.November 8, 2023 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)November 7, 2023 | bizjournals.comActivist investor takes stake in BioMarin as drug maker switches out CEOsNovember 7, 2023 | markets.businessinsider.comActivist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO ChangeNovember 7, 2023 | msn.comBiggest stock movers today: BioMarin, Alteryx, Tripadvisor and moreNovember 7, 2023 | finance.yahoo.comBioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion StakeNovember 7, 2023 | investorplace.comBMRN Stock Jumps 12% as Activist Elliott Targets BioMarin PharmaceuticalsNovember 7, 2023 | ca.finance.yahoo.comExclusive-Activist investor Elliott targets drugmaker BioMarin -sourcesNovember 7, 2023 | seekingalpha.comBioMarin: Keeping Bullish View After Q3 EarningsNovember 2, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Theravance Biopharma (TBPH), BioMarin Pharmaceutical (BMRN)November 2, 2023 | finance.yahoo.comBioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View CutNovember 2, 2023 | finance.yahoo.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call TranscriptNovember 1, 2023 | bizjournals.comGenentech CEO Alexander Hardy resigns effective immediately to replace Jean-Jacques Bienaimé as CEO at BioMarinNovember 1, 2023 | finance.yahoo.comBioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive OfficerNovember 1, 2023 | finance.yahoo.comBioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over YearNovember 1, 2023 | finance.yahoo.comBiomarin Pharmaceutical Inc (BMRN) Reports 15% Total Revenue Growth in Q3 2023November 1, 2023 | finance.yahoo.comBioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesNovember 1, 2023 | seekingalpha.comBioMarin Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call PresentationOctober 27, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin PharmaceuticalSee More Headlines Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,082Year Founded1997Price Target and Rating Average Stock Price Target$112.65 High Stock Price Target$185.00 Low Stock Price Target$78.00 Potential Upside/Downside+18.7%Consensus RatingModerate Buy Rating Score (0-4)2.61 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$0.77 Trailing P/E Ratio123.30 Forward P/E Ratio80.46 P/E Growth1.44Net Income$141.56 million Net Margins6.36% Pretax Margin6.56% Return on Equity4.45% Return on Assets3.23% Debt Debt-to-Equity Ratio0.12 Current Ratio2.54 Quick Ratio1.65 Sales & Book Value Annual Sales$2.10 billion Price / Sales8.53 Cash Flow$1.51 per share Price / Cash Flow62.73 Book Value$24.82 per share Price / Book3.83Miscellaneous Outstanding Shares188,370,000Free Float184,902,000Market Cap$17.88 billion OptionableOptionable Beta0.40 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Jean-Jacques Bienaime M.B.A. (Age 70)Chairman & CEO Comp: $3.52MMr. Brian R. Mueller (Age 49)CFO & Executive VP Comp: $1.15MMr. George Eric Davis (Age 52)Executive VP, Chief Legal Officer, General Counsel & Secretary Comp: $1.23MMr. Jeffrey Robert Ajer (Age 61)Chief Commercial Officer Comp: $1.18MDr. Henry J. Fuchs M.D. (Age 65)Ph.D., President of Worldwide Research & Development Comp: $1.49MMs. Erin BurkhartGroup VP & Chief Accounting OfficerDr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentTraci McCartyGroup Vice President of Investor RelationsMr. Philip Lo ScalzoChief Compliance OfficerMs. Marni KottleChief Communications OfficerMore ExecutivesKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYMyoKardiaNASDAQ:MYOKUnited TherapeuticsNASDAQ:UTHRImmunoGenNASDAQ:IMGNIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 77,910 shares on 12/7/2023Ownership: 0.069%American Century Companies Inc.Bought 956 shares on 11/30/2023Ownership: 0.279%Walleye Capital LLCBought 10,700 shares on 11/21/2023Ownership: 0.000%Walleye Trading LLCSold 30,800 shares on 11/21/2023Ownership: 0.000%Braun Stacey Associates Inc.Sold 177,727 shares on 11/21/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions BMRN Stock Analysis - Frequently Asked Questions Should I buy or sell BioMarin Pharmaceutical stock right now? 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks. What is BioMarin Pharmaceutical's stock price target for 2024? 23 brokers have issued 1-year price targets for BioMarin Pharmaceutical's stock. Their BMRN share price targets range from $78.00 to $185.00. On average, they expect the company's stock price to reach $112.65 in the next year. This suggests a possible upside of 18.7% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts. How have BMRN shares performed in 2023? BioMarin Pharmaceutical's stock was trading at $103.49 at the start of the year. Since then, BMRN stock has decreased by 8.3% and is now trading at $94.94. View the best growth stocks for 2023 here. Are investors shorting BioMarin Pharmaceutical? BioMarin Pharmaceutical saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 3,080,000 shares, a drop of 6.4% from the October 31st total of 3,290,000 shares. Based on an average trading volume of 1,520,000 shares, the days-to-cover ratio is currently 2.0 days. View BioMarin Pharmaceutical's Short Interest. When is BioMarin Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our BMRN earnings forecast. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by $0.02. The biotechnology company had revenue of $581.33 million for the quarter, compared to analyst estimates of $603.51 million. BioMarin Pharmaceutical had a net margin of 6.36% and a trailing twelve-month return on equity of 4.45%. What ETFs hold BioMarin Pharmaceutical's stock? ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV), First Trust Innovation Leaders ETF (ILDR) and VictoryShares Nasdaq Next 50 ETF (QQQN). What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical issued an update on its fourth quarter earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of $0.08-0.28 for the period, compared to the consensus earnings per share estimate of $0.27. The company issued revenue guidance of $617-697 million, compared to the consensus revenue estimate of $652.66 million. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.77%), Barclays PLC (2.96%), Ameriprise Financial Inc. (2.74%), Fort Washington Investment Advisors Inc. OH (0.70%), Charles Schwab Investment Management Inc. (0.69%) and Northern Trust Corp (0.65%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BMRN) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.